

Index

- ABC *see* ATP-binding cassette
ABC transporters 169–70, 172,
174, 176, 178, 180, 182,
184
ACE *see* angiotensin-converting
enzyme
activated platelets 8–9, 372,
409–10, 413, 416, 420,
432, 451
activity
 aminopeptidase 94–95
 anti-atherogenic 105, 174
 chemotactic 4, 36, 374
acute coronary syndromes 86, 92,
120, 151, 201, 256, 273,
282, 292, 297, 380,
399–401, 405, 427–28, 431
acute myocardial infarction (AMI)
 127, 142–44, 157, 230,
 237, 251, 254, 299, 367,
 412, 428, 433
adhesion molecules 2, 43–44, 88,
229, 315, 347, 377, 412,
420, 436, 442, 449–51
 junctional 416–17, 437
advanced atherosclerosis 51, 134,
144, 149, 299, 303, 308,
311, 314, 317, 319, 321,
323, 336
advanced lesions 38, 303, 311–13,
315
adventitia 127–28, 134, 141, 157
agents, anti-platelet 399, 401,
403–4
AMI
 see acute myocardial infarction
experimental 144
AngII receptor blockers (ARBs)
 222–23, 232
angina, unstable 91, 101, 142,
292, 367, 398, 450
angiogenesis 35, 124, 135, 137,
260, 266, 347, 353
angiotensin-converting enzyme
 (ACE) 217–24, 227, 229,
231–32, 238, 240, 242–43,
246, 251–52, 346
angiotensin-converting enzyme
 inhibition 220, 239, 241
angiotensin peptides 218–19,
225, 227
angiotensinogen 217–18, 221,
223, 225, 227, 231, 233,
251, 254
antagonistic activity 375–76
antagonists 13, 15–16, 27, 145,
153, 161, 239, 372–73,
375–76, 387–88, 398,
400–1, 416, 419, 435–36
chemokine receptor 16, 18,
30
 selective 375–76
thrombin receptor 404
thromboxane receptor 403
anti-oxidant activity 285, 287,
290
anti-platelet therapies 185,
393–94, 399–400, 403, 421
antibodies 18, 43, 47–49, 70, 83,
106, 127, 150, 366, 413,
433
 blocking 12–14, 447

- antigen presenting cells (APCs) 165, 412, 437, 442, 444–45, 447, 451
- APCs *see* antigen presenting cells
- apoptosis 59, 67, 132–34, 142, 146, 153, 256–57, 267–69, 272, 291, 302, 304–7, 312, 331–33, 335–36
stress-induced 300, 302, 308, 310, 327, 332, 336
- apoptotic cell clearance 311–12, 314, 316, 322, 329, 331, 334
- apoptotic cell engulfment 311, 313, 316–17, 333
- apoptotic cells 311, 314–15, 317–18, 325, 327–35, 338
- arachidonic acid 85–86, 105, 157, 187
- ARBs *see* AngII receptor blockers
- arterial thrombosis 132, 394, 405, 407, 428–30
- aspirin 88, 117, 187, 213, 275, 377, 393, 395–99, 402–5, 421, 423–27, 430
- asthma 107, 123, 128, 141, 145, 149, 151, 156
- AT1 receptor antagonism 230, 232
- AT1 receptor stimulation 218–19
- AT1 receptors 218, 223, 226, 229, 231
- AT2 receptors 218–19, 224–25, 231, 242
- atherogenesis 8–9, 24–26, 32–33, 38–42, 44, 70–71, 82–83, 87–91, 104–5, 114–16, 137–38, 140–42, 145–47, 242–43, 420–22
human 115, 120
- atherogenic macrophage function 349, 351
- atherosclerosis prevention of 246, 255–56, 258, 260, 264, 266, 270, 272, 274, 276, 278, 280, 282, 445
therapeutic approach to 31–32, 34, 36, 38, 40, 42, 46, 48, 50, 52, 56, 58, 60, 62
- atherosclerotic cardiovascular disease 87, 170, 175
- atherosclerotic diseases 16, 30, 230–31, 233–35, 285, 296
- atherosclerotic lesion development 9, 26, 72, 76, 107
- atherosclerotic lesion formation 9, 12, 17, 24, 26, 163, 195–96, 229, 347–48, 365, 372, 384, 418, 436
- atherosclerotic lesions 28–29, 38–39, 92–94, 98–99, 101, 126–27, 133–34, 220, 227, 229–31, 366–67, 371–72, 377–79, 409–11, 418
advanced 280, 308, 327, 329
- atherosclerotic plaque progression 39, 149, 166, 273
- atherosclerotic plaques 12, 26–27, 32, 38, 77, 87–89, 92, 108, 154, 199, 277–78, 280–82, 336–37, 348–49, 444
- atherothrombotic events 396, 398, 400
- ATP-binding cassette (ABC) 35, 143, 169, 171, 180, 245
- autoimmune encephalomyelitis, experimental 69–70, 137
- bioactive peptides 217–19, 227
- biogenesis 342–43, 355–56

- bone marrow 12, 30, 70, 124, 173–74, 180, 227, 243, 247, 290, 305, 382, 419, 444, 448–49
- c-Jun N-terminal kinase (JNK) 160, 263, 302, 304, 333, 339, 350, 453
- C-reactive protein (CRP) 14, 28, 196, 198–99, 201, 234, 290, 292–93
- C-terminal domains 91, 258, 260
- CAD *see* coronary artery disease
- cancer 31, 49–50, 56, 137, 276, 302, 320, 322, 330, 395, 422, 424
- captopril 220–21, 239
- cardiovascular diseases 1–2, 14, 31, 33, 40, 54, 117–18, 150–51, 205–6, 232, 318–19, 353–54, 377–78, 447, 451–53
- cardiovascular events 170, 178–79, 181, 185, 194, 196, 198, 207, 211, 232, 237, 396–97, 404–5, 420–21, 423
- cardiovascular risk 59, 110, 170, 186, 197–98, 232, 251, 253, 381, 397
- cell adhesion 42, 44, 132, 134
- cell adhesion molecules 359, 371–72, 383
- cell death 186, 299–300, 302, 327–28
- cell survival 56, 84, 300, 302, 313–14, 317, 328, 335, 381, 446
- cells, immune 86, 300, 393, 409, 419, 441–42, 447–48, 450
- CETP *see* cholesteryl ester transfer protein
- CHD *see* coronary heart disease
- chemokine functions 11–12
- chemokine-like function (CLF) 31, 33, 45–46, 49, 51
- chemokine oligomerization 4, 20
- chemokine receptors 3–4, 6, 13, 15–16, 18, 21, 24, 30, 36–37, 45–46, 50, 60, 229, 315, 415
- chemokine system 2–3, 6, 13, 15–18, 29, 62
- chemokines 1–24, 26, 28, 32–33, 52–53, 56–57, 123–24, 127, 248, 371–72, 374, 383–84, 409–11, 414–20, 438–39
- platelet 8, 385
- presentation of 4, 6–8
- cholesterol, excess 169–72
- cholesterol efflux 136, 155, 158, 169–76, 178–80, 182–84
- cellular 136, 143, 172, 174, 180
- cholesteryl ester transfer protein (CETP) 51, 177–78, 183
- cholesteryl ester transfer protein inhibition 183
- chronic obstructive pulmonary disease (COPD) 373, 416
- chymase 125, 127, 129, 132, 134–37, 142–45, 153, 158–59, 161, 165–66, 219, 265
- chymase activity 144
- chymase inhibition 145, 155
- chymase inhibitors 143–44, 153–54, 164
- cilostazol 401–2, 427
- circulating monocytes 88, 349

- CLF *see* chemokine-like function
 clopidogrel 393, 398–400, 402,
 405, 423, 425–27
 co-stimulatory molecules 126,
 412, 443, 447, 450, 455
 coronary arteries, human
 atherosclerotic 91
 coronary artery disease (CAD)
 91, 101, 105, 129, 193,
 197, 203–4, 206, 213–14,
 233–34, 252–53, 352–54,
 362, 390, 445
 coronary heart disease (CHD) 32,
 40, 58, 143, 185, 196–97,
 199, 206–7, 251, 254, 351
 coronary syndromes 331, 378,
 425, 439, 462
 CRP *see* C-reactive protein
 CsH *see* cyclosporin H
 cyclooxygenases 85–86, 109, 116,
 121–22, 395
 cyclosporin H (CsH) 375, 387–88
 cyclosporins 375, 387–88
 cysteine 258–60
 cysteinyl leukotrienes 91, 113,
 115, 120–22
 cytokines 10, 33–34, 44, 46, 49,
 52, 54, 59, 61, 67, 138, 369,
 409–11, 419–20, 449–50
 latent 136–37, 142
 darapladib 186–88, 193–94,
 198–200, 209
 DCs *see* dendritic cells
 defective efferocytosis 299–300,
 312, 318–19, 321
 dendritic cells (DCs) 36, 46, 61,
 67, 69, 71–73, 81–82, 86,
 92, 124, 126, 316, 349,
 444–45, 448–50
 diabetes 74, 76, 178, 181–82, 198,
 242, 253, 285, 302,
 308–11, 324, 326–28,
 332–33, 335, 389
 dipyridamole 402–3, 427
 diseases, immune 49–50
 drugs, antithrombotic 397–98,
 406
 dyslipidemia 308–9, 311, 323,
 370
 ECs *see* endothelial cells
 efferocytosis 299–300, 302, 304,
 306, 308, 310–14, 316–22,
 324, 326, 328, 330–32,
 334, 336–39
 efferocytosis therapy 311, 313,
 315, 317
 eicosanoid pathways 87
 eicosanoids 85–86, 88, 93, 98,
 107, 113, 187, 191, 205,
 316
 endoplasmic reticulum (ER) 267,
 300–4, 308–10, 313, 320,
 324–25, 327–28, 330, 332,
 334, 336–37, 339
 endoplasmic reticulum stress
 325, 328–29, 332, 336–37
 endothelial cells (EC) 2, 8, 34–35,
 38, 41, 88, 101–2, 124,
 228–30, 325–26, 347–50,
 352, 359–60, 410–13,
 419–20
 endothelial cells (ECs) 34–35, 38,
 88, 101–2, 228–30, 261,
 265–66, 300, 306, 325–26,
 347–50, 359–60, 410–13,
 419–20, 451–52
 endothelial dysfunction 228, 307,
 310–11, 349, 377–78
 endothelial function 102, 377–78,
 382, 390
 endothelium 8–9, 19, 24, 38, 89,
 160, 229, 276, 306,
 373–74, 385, 390, 394,
 410, 417–18
 ER *see* endoplasmic reticulum
 ER stress 300–1, 303–11, 313,
 320–21, 332, 334

- ER stress therapy 300, 303, 305, 307, 309
- experimental atherosclerosis 76, 125, 127, 137–41, 218–19, 221, 229–30, 287
- five lipoxygenase activating protein (FLAP) 90, 93–96, 114, 117
- FLAP *see* five lipoxygenase activating protein
- FLAP gene variants 93
- FLAP inhibitors 93–94
- foam-cell formation 124, 135–36
- focal adhesion kinase (FAK) 134, 279
- functions, regulatory T-cell 455
- G protein-coupled receptor (GPCR) 3, 37, 44, 96
- genes, protein-coding 342
- genetic manipulation 223–25, 271
- glycosaminoglycans 3–4, 20, 211
- GPCR *see* G protein-coupled receptor
- granule proteins 368, 374–76
- HDL
- see* high-density lipoprotein
 - circulating 170, 172
- heme oxygenase-1 288, 290, 295–98
- hepatic activation 399–400
- high-density lipoprotein (HDL) 47, 135–36, 140, 167, 169–70, 172, 174, 176–84, 192, 197, 348, 359
- histamine 123–24, 126, 129, 131, 135, 141, 146, 150, 153, 155, 162, 165
- HIV *see* human immunodeficiency virus
- homocysteine 306–7, 325, 328, 332, 339
- human atherosclerosis 38, 55, 92, 95, 109, 147, 149, 153, 194, 231, 283, 297, 418, 462
- human atherosclerotic diseases 178, 233–34
- human atherosclerotic lesions 51, 87–88, 92, 99, 118, 125, 127, 129, 131, 134, 142, 163, 194, 231, 250
- human atherosclerotic plaques 57–58, 91, 99, 109–10, 128, 210, 231, 273, 337, 444, 451–52, 456
- destabilization of 58
- human carotid atherosclerotic plaques 92, 379, 451
- human coronary atheromas 155, 250
- human immunodeficiency virus (HIV) 15
- human monocytes, primary 351–52
- human plaques 41, 94, 269, 274
- human platelets 210, 435–37
- human umbilical vein endothelial cells (HUVECs) 102, 226
- HUVECs *see* human umbilical vein endothelial cells
- hypercholesterolemia 198, 226–27, 236, 241, 245, 285, 348, 367–70, 378, 381, 432, 449
- hypercholesterolemic patients 286
- hyperglycemia 38, 307–10

- hyperlipidemia 1–2, 12, 309, 320, 346, 353, 367–69, 380, 390
- hypertension 148, 154, 220, 223, 235–39, 241, 246, 248–51, 253, 285, 313, 368, 390–91
- hypertensive patients 234, 377
- hypoxia 34, 38, 264, 337, 355
- immune suppression 67, 77, 455
- immunity, adaptive 61, 106, 125–26, 147, 386, 451, 462
- infection 18, 30, 80, 126, 160, 191, 193, 204
- inflammatory cells 13, 34, 40, 96, 127–28, 138, 160, 163, 255, 287, 397, 420, 442, 448–49, 451
- inflammatory genes 263–65, 326
- inflammatory monocytes 300, 369, 374–75
- inflammatory responses 14–15, 23, 88, 99–100, 109, 111, 149, 186, 190, 211, 229, 290, 328–29, 346, 360–62
- inhibition, metalloproteinase 282
- insulin resistance (IR) 58, 308–11, 319–20
- interleukin 32, 82, 250, 277, 361, 457–58
- intimal hyperplasia 100–1, 103, 106, 114, 144, 286, 288, 294
- intraplaque hemorrhage 127, 140–41, 144, 149, 269–70, 367, 380
- IR *see* insulin resistance
- ischemic stroke 2, 93, 96, 114, 116, 122, 402–3, 449
- JNK *see* c-Jun N-terminal kinase
- junctional adhesion molecules (JAMs) 416–17, 436–37
- LDL *see* low-density lipoprotein
- LDL oxidation 377–78
- leptin 75–76, 83–84, 135
- lesion development 52, 73, 77–78, 140
- lesion progression 31, 52–53, 312
- leukocyte activation 100, 190
- leukocyte recruitment 9, 42, 45–46, 49, 134, 186, 397, 409–12, 420, 449
- atherogenic 31–32, 35, 43–44, 52, 61
- leukocyte subsets 6, 50, 358, 379, 410, 416
- leukocytes 2, 4, 6, 9–10, 25, 31–32, 57, 59, 88, 90, 92, 97–99, 195, 381–84, 410–12
- polymorphonuclear 104, 365, 380–82, 399
- leukotriene receptors 87, 96–97, 99, 101–2, 117
- leukotrienes 85–86, 97, 106, 109–11, 113, 115, 117–19, 152, 159, 205, 316, 410
- lipoprotein lipid oxidation 287–88
- lipoprotein metabolism 188–89, 191–92, 205, 370
- lipoproteins 58, 122, 129, 131, 156, 159, 177, 180, 182–84, 189, 192, 203, 205, 207, 210
- high-density 47, 169, 179, 181–83, 359
- lipoxins 85–86, 113, 316, 327
- liver 169–70, 174, 189, 194, 218, 227, 309, 318, 328, 334, 398, 451
- liver X receptors (LXRs) 174, 180, 318
- low-density lipoprotein (LDL) 2, 25, 34, 82, 104, 107–8, 124, 163–64, 170, 180, 205–6, 212–14, 245–46, 380–81, 442

- LXRs *see* liver X receptors
- lymphocytes 38, 66, 69, 71–73, 77, 82–83, 124, 366, 369, 412
- macrophage activation 264, 373, 375, 451
- macrophage apoptosis 141, 274, 276, 303, 311, 320, 326, 335–36
- macrophage cholesterol efflux 169, 172–73, 178, 183
- macrophage migration 10, 53–54, 56–59, 61–62, 268, 270, 275, 280
- macrophage migration inhibitory factor 31, 54–60, 62
- MAP *see* mitogen-activated protein
- MAPKs *see* mitogen-activated protein kinases
- mast cell activation 114, 129, 151, 156
- mast cell chymase 133, 158, 163–65
- mast cell functions 130, 160, 162, 167
- mast cells 50, 92, 114, 123–28, 130–38, 140–42, 144–67, 193, 195, 219, 238, 265, 442, 447–48
human 148–49, 152–55, 162
- metalloproteinases 88, 124, 257–58, 276–78, 315
- MI *see* myocardial infarction
- microRNAs 341–44, 346, 348, 350, 352, 354–62
- microvesicles 348, 352–54
- MIF
see migration inhibitory factor
human 33
- MIF antagonism 31–32, 34, 36, 38, 40, 42, 46, 48, 50, 52, 54, 56, 58, 60, 62
- MIF expression 38–39, 60
- MIF-induced monocyte adhesion 43, 52
- MIF receptors 36–37, 49
- MIF secretion 34–35, 42, 47
- migration inhibitory factor (MIF) 31–59, 62–63
- mitogen-activated protein (MAP) 228, 349, 351, 362, 453
- mitogen-activated protein kinases (MAPKs) 228, 230, 263
- monocyte adhesion 32, 42–43, 228–29, 417
- monocyte arrest 21–23, 60, 384–85, 409, 418, 432, 438
- monocyte chemoattractant protein (MCP) 100
- monocytes 5–6, 12, 14, 37–38, 41–44, 88–89, 228–30, 261, 268, 275–77, 351–52, 368–69, 374, 379–80, 417–20
- monomers 4, 33, 93, 95
- myocardial infarction (MI) 40, 89, 91, 93, 95, 114, 154–55, 157, 234, 251–52, 256, 292, 368, 395–96, 402–3
- myocardin 345–46
- neointima formation 9, 23, 40, 278, 345, 347, 407, 419, 437, 454–55, 465
- neutrophil elastase 374, 387
- neutrophilia 12, 138, 367, 369
- neutrophilic granulocytes 365–66, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390
- neutrophils 9–10, 12, 15, 26, 36, 44, 50, 60, 86, 92, 99, 124–25, 150, 379–82, 385–87

- non-steroidal anti-inflammatory drugs (NSAIDs) 90, 117, 187, 395, 423
- NSAIDs *see* non-steroidal anti-inflammatory drugs
- nucleotides 115, 343, 351
- obesity 1, 161, 285, 308–11, 318, 326, 339
- oligomerization 3–4, 20, 27, 29, 419
- oxidative stress 88, 116, 243, 246, 308, 310, 314, 328, 335, 377–78, 380, 389, 391
- oxidized phospholipids 189–90, 203, 213, 306, 308
- PAF *see* platelet activating factor
- PARs *see* protease-activated receptors
- patients
- dyslipidemic 370
 - hyperlipidemic 370, 378
- PCI *see* percutaneous coronary intervention
- percutaneous coronary intervention (PCI) 291–92, 297, 399–401, 427
- peroxisome proliferator activator receptors (PPARs) 222, 234, 264, 318
- peroxynitrite 308, 325, 333
- phagocytes 314–18, 327, 329
- phagocytosis 323–24, 327, 330–31, 338–39
- phospholipase, lipoprotein-associated 203–4, 206
- phospholipids 103, 187, 191–92, 204, 212–13
- picotamide 403–4, 427
- PKA *see* protein kinase A
- PKC *see* protein kinase C
- PLA *see* platelet-leukocyte aggregates
- plaque development 10, 39, 41, 77, 90, 272
- plaque formation, accelerated 38, 40, 348
- plaque inflammation 41, 274–75, 444, 462
- plaque instability 57, 89, 101, 108, 115, 194, 250, 272, 275, 292, 303, 312, 459
- plaque necrosis 304, 310, 317, 336
- plaque progression 12, 38, 81, 274, 336, 448
- plaque regression 12–13, 39, 176
- plaques, stable 375, 397, 448
- plasma, human 136, 189–90, 212–13
- plasma platelet 212, 214
- platelet-activating factor 206–8, 210, 213, 215
- platelet activating factor (PAF) 188–89, 193, 205, 209, 409–10
- platelet activation 89, 109–10, 393–95, 397, 399, 401, 405, 408, 410, 413–14, 419, 430, 436
- platelet adhesion 24, 384, 394, 405–6, 410, 415, 420, 429, 431, 439
- platelet aggregation 86, 110, 393–95, 398, 401–2, 407–8, 413, 449
- platelet-derived-growth-factor (PDGF) 42, 261, 345
- platelet functions 403, 424
- platelet glycoprotein 429

- platelet-leukocyte aggregates
(PLA) 197, 214, 410, 412,
417
- platelet microparticles 24
- platelet-monocyte complexes
(PMC) 410
- platelet tethering 394
- PMN *see* polymorphonuclear leukocytes
- PMN adhesion 368, 371–72
- PMN extravasation 371–72
- PMN granule proteins 373–75
- polymorphism 40, 96, 111, 114,
198, 205, 215, 233–34,
251–54, 361, 426, 435
- polymorphonuclear leukocytes
(PMN) 365–76, 379, 399,
417
- PPARs *see* peroxisome proliferator activator receptors
- PPIs *see* proton pump inhibitors
- prasugrel 399–400, 426
- probucol 286–98, 389
- probucol analogues 286, 289,
291, 293, 296
- probucol derivatives 293
- prostanoids 86–87, 89
- protease-activated receptors
(PARs) 375, 404, 451
- protein kinase A (PKA) 149, 316,
325, 401
- protein kinase C (PKC) 146, 228,
263, 277
- proteins
- contractile 344–47
 - misfolded 301, 305
- proteolysis 135, 157, 255–56,
268, 374
- proton pump inhibitors (PPIs)
399, 426
- ramipril 221, 232, 237, 241, 246,
390
- RAS *see* renin angiotensin system
- RAS Inhibition 218, 231–32
- RCT *see* reverse cholesterol transport
- reactive oxygen species (ROS)
228, 242, 246, 264, 278,
302, 304, 308, 370, 376–77,
382, 389, 391, 399, 402
- renin 217–19, 223, 225, 227, 231,
235, 242, 245, 252
- renin angiotensin system (RAS)
217–21, 223–28, 230–36,
238, 240, 242, 244, 246,
248, 250, 252, 254
- renin inhibition 223, 230, 236
- restenosis 100–1, 282, 291–92,
326, 389, 461
- retinoic acid 69–70, 81
- reverse cholesterol transport
(RCT) 169–71, 173,
176–78, 408
- ROS *see* reactive oxygen species
- SCF *see* stem cell factor
- selectins 371–72, 411, 433
- self-tolerance 66–67, 83
- serotonin 150, 398, 404, 407–8,
430
- simvastatin 370–71, 382–83
- single nucleotide polymorphisms
(SNPs) 233–34, 438, 447
- SMC *see* smooth muscle cells
- SMC apoptosis 132, 142, 344
- SMC proliferation 129, 146,
345–47
- smooth muscle cell proliferation
228, 230, 249, 279, 295
- smooth muscle cells (SMCs) 2, 32,
38–40, 42, 59–60, 88–89,
97, 131–33, 226–30,
276–77, 279, 291, 307,
344–47, 357–58

- SNPs *see* single nucleotide polymorphisms
- spleen 69, 71, 75, 195, 413, 444–45
- statins 18, 90, 170, 178, 185, 201, 226, 313, 370–71, 378, 383, 390, 421
- stem cell factor (SCF) 124–25, 127, 131, 149
- succinobucol 289–94, 296–97
anti-inflammatory activity of 290
- therapeutic targeting 13, 15, 17
- thrombin 102, 132, 257, 383, 395, 398, 404, 409, 415
- thrombocytopenia 414, 435
- thrombotic thrombocytopenia purpura (TTP) 406
- thrombus formation 230, 394, 412, 422, 428, 433
- TLRs *see* Toll-like receptors
- TNF *see* tumor necrosis factor
- TNF-R associated factor (TRAF) 302, 304, 449, 452–53, 455, 464
- Toll-like receptors (TLRs) 190, 414
- torcetrapib 178
- TRAF *see* TNF-R associated factor
- tranilast 141–42, 145, 155, 157
- Treg cells 66–71, 73–74, 76–78
suppressive function of 68, 76
- tumor necrosis factor (TNF) 32, 34, 38, 41, 45, 125–27, 131, 134, 138, 142, 287, 289–90, 350–52, 417–18, 454–55
- unfolded protein response (UPR) 301–4, 307, 309–10, 312, 320, 326, 330, 334, 338
- UPR *see* unfolded protein response
- vascular cell adhesion molecule (VCAM) 229, 247, 315, 347
- vascular cells 4, 104, 131, 258, 260–61, 265–67, 272–73, 334, 416
- vascular endothelial growth factor (VEGF) 135, 347, 351
- vascular inflammation 99, 108, 153, 229–30, 236, 352, 359, 419, 424, 433
- vascular injury 24, 42, 57, 102, 289, 291, 345–46, 394–95, 418, 429, 433
- vascular integrity 347, 359
- vascular smooth muscle cell (VSMC) 59–60, 88, 97, 100–1, 230, 248–49, 256, 261, 263–66, 270, 276, 287, 291, 300, 307
- vascular tone 89, 101–2
- VCAM *see* vascular cell adhesion molecule
- vitronectin 134
- von Willebrand factor (VWF) 394–95, 405–7, 410, 416, 428–29, 432
- VSMC *see* vascular smooth muscle cell
- VSMC proliferation, inhibiting 289
- VWF *see* von Willebrand factor

“While the artery is the conduit of blood and nutrients, its lining can be subject to intense inflammation that is the underpinning of heart attacks, strokes, and sudden death. In Atherosclerosis: Treatment and Prevention, Weber and Soehnlein have put together a comprehensive assessment of the science behind atherosclerosis and arterial inflammation, culling together an impressive group of expert contributors who cover the field exceptionally well.”

Prof. Eric J. Topol
The Scripps Research Institute, USA

“This is an authoritative book written and edited by leaders in the field who have provided a historical context while focusing on recent exciting literature. Should appeal to graduate students, physicians, and seasoned scientists alike.”

Prof. Filip K. Swirski
Harvard Medical School, USA

“I am convinced that this volume will offer an interesting reading for scientists and clinicians working in the field of atherosclerosis and provide an excellent introduction for those entering this area of research.”

Prof. Göran Hansson
Karolinska Institutet, Sweden

In recent years, the understanding of the pathophysiological processes of atherosclerosis, a chronic inflammatory disease of the vessel walls that is the leading cause of mortality in industrial countries, has tremendously increased. The feasibility of translating such knowledge to novel therapeutic approaches is currently being explored at various levels. This book aims to highlight recent advances in atherosclerosis and link these to relevant therapeutic strategies. It compiles and details cutting-edge research in cardiovascular medicine by internationally renowned authors. The text will appeal to anyone involved in cardiovascular research, inflammation, and drug development.



Christian Weber is director of the Institute for Cardiovascular Prevention and chair in Vascular Medicine at Ludwig-Maximilians-University (LMU), Munich, Germany. His research is focused on elucidating and targeting functional interactions of chemokines, microRNAs, and immune cell subsets in atherosclerosis. He is an ERC Advanced Investigator, VICI laureate, professor at Maastricht University, the Netherlands, editor-in-chief of *Thrombosis & Haemostasis*, and co-founder of Carolus Therapeutics Inc.



Oliver Soehnlein is a group leader at the Institute of Cardiovascular Prevention at LMU, where he leads a research group focusing on the cellular interplay between myeloid cell subsets in acute and chronic inflammatory conditions. He received his MD in 2004 from the University of Erlangen, Germany, and then continued his research at Karolinska Institutet, Sweden, where he received his PhD in physiology in 2008.



PAN STANFORD PUBLISHING
www.panstanford.com

